These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 15307856)

  • 21. Impact of Helicobacter pylori eradication on the anti-secretory efficacy of lansoprazole in gastroesophageal reflux disease patients.
    Giral A; Celikel CA; Ozdogan O; Tözün N; Ulusoy NB; Kalayci C
    J Gastroenterol Hepatol; 2005 Dec; 20(12):1886-91. PubMed ID: 16336449
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis.
    Kahrilas PJ; Dent J; Lauritsen K; Malfertheiner P; Denison H; Franzén S; Hasselgren G
    Clin Gastroenterol Hepatol; 2007 Dec; 5(12):1385-91. PubMed ID: 17950677
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of Helicobacter pylori eradication on development of erosive esophagitis and gastroesophageal reflux disease symptoms: a post hoc analysis of eight double blind prospective studies.
    Laine L; Sugg J
    Am J Gastroenterol; 2002 Dec; 97(12):2992-7. PubMed ID: 12492181
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of three different dosages of esomeprazole in the long-term management of reflux disease: a prospective, randomized study, using the wireless Bravo pH system.
    Vasiliadis KV; Viazis N; Vlachogiannakos J; Sgouros SN; Stefanidis G; Archimandritis A; Karamanolis DG
    Am J Gastroenterol; 2010 Feb; 105(2):308-13. PubMed ID: 19809412
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gastroesophageal reflux disease and Helicobacter pylori infection.
    Vakil N
    Rev Gastroenterol Disord; 2003; 3(1):1-7. PubMed ID: 12684588
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Do some patients with Helicobacter pylori infection benefit from an extension to 2 weeks of a proton pump inhibitor-based triple eradication therapy?
    Maconi G; Parente F; Russo A; Vago L; Imbesi V; Bianchi Porro G
    Am J Gastroenterol; 2001 Feb; 96(2):359-66. PubMed ID: 11232676
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intra-oesophageal acid suppression in complicated gastro-oesophageal reflux disease: esomeprazole versus lansoprazole.
    Frazzoni M; Manno M; De Micheli E; Savarino V
    Dig Liver Dis; 2006 Feb; 38(2):85-90. PubMed ID: 16289976
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Minimal change esophagitis: prospective comparison of endoscopic and histological markers between patients with non-erosive reflux disease and normal controls using magnifying endoscopy.
    Kiesslich R; Kanzler S; Vieth M; Moehler M; Neidig J; Thanka Nadar BJ; Schilling D; Burg J; Nafe B; Neurath MF; Galle PR
    Dig Dis; 2004; 22(2):221-7. PubMed ID: 15383765
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of H. pylori status on gastric ulcer healing in patients continuing nonsteroidal anti-inflammatory therapy and receiving treatment with lansoprazole or ranitidine.
    Campbell DR; Haber MM; Sheldon E; Collis C; Lukasik N; Huang B; Goldstein JL
    Am J Gastroenterol; 2002 Sep; 97(9):2208-14. PubMed ID: 12358234
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study.
    Labenz J; Armstrong D; Lauritsen K; Katelaris P; Schmidt S; Schütze K; Wallner G; Juergens H; Preiksaitis H; Keeling N; Nauclér E; Eklund S;
    Aliment Pharmacol Ther; 2005 Mar; 21(6):739-46. PubMed ID: 15771760
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Esomeprazole 40 mg administered intravenously has similar safety and efficacy profiles to the oral formulation in patients with erosive esophagitis.
    Schneider H; Van Rensburg C; Schmidt S; Aboo N; Makela H; Nauclér E; Hallerback B; Svedberg LE
    Digestion; 2004; 70(4):250-6. PubMed ID: 15687727
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lower prevalence of Helicobacter pylori infection with vacAs1a, cagA-positive, and babA2-positive genotype in erosive reflux esophagitis disease.
    Lai CH; Poon SK; Chen YC; Chang CS; Wang WC
    Helicobacter; 2005 Dec; 10(6):577-85. PubMed ID: 16302983
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the efficacy of 1-day high-dose quadruple therapy versus 7-day triple therapy for treatment of Helicobacter pylori infection.
    Zheng Q; Pan Y; Zhang L; Xiao SD
    Chin J Dig Dis; 2005; 6(4):202-5. PubMed ID: 16246231
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation--results from two randomized controlled studies.
    Sharma P; Shaheen NJ; Perez MC; Pilmer BL; Lee M; Atkinson SN; Peura D
    Aliment Pharmacol Ther; 2009 Apr; 29(7):731-41. PubMed ID: 19183157
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Daily treatment with esomeprazole is superior to that taken on-demand for maintenance of healed erosive oesophagitis.
    Sjöstedt S; Befrits R; Sylvan A; Harthon C; Jörgensen L; Carling L; Modin S; Stubberöd A; Toth E; Lind T
    Aliment Pharmacol Ther; 2005 Aug; 22(3):183-91. PubMed ID: 16091055
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Male sex, hiatus hernia, and Helicobacter pylori infection associated with asymptomatic erosive esophagitis.
    Wang PC; Hsu CS; Tseng TC; Hsieh TC; Chen CH; Su WC; Lin HH; Wang CC
    J Gastroenterol Hepatol; 2012 Mar; 27(3):586-91. PubMed ID: 21871022
    [TBL] [Abstract][Full Text] [Related]  

  • 37. H. pylori eradication prevents the progression of gastric intestinal metaplasia in reflux esophagitis patients using long-term esomeprazole.
    Yang HB; Sheu BS; Wang ST; Cheng HC; Chang WL; Chen WY
    Am J Gastroenterol; 2009 Jul; 104(7):1642-9. PubMed ID: 19436275
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Eight weeks of esomeprazole therapy reduces symptom relapse, compared with 4 weeks, in patients with Los Angeles grade A or B erosive esophagitis.
    Hsu PI; Lu CL; Wu DC; Kuo CH; Kao SS; Chang CC; Tai WC; Lai KH; Chen WC; Wang HM; Cheng JS; Tsai TJ; Chuah SK
    Clin Gastroenterol Hepatol; 2015 May; 13(5):859-66.e1. PubMed ID: 25245625
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [In-vitro activity of rabeprazole, lansoprazole, and esomeprazole against Helicobacter pylori].
    He LH; Yin Y; You YH; Yan XM; Zhang JZ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Jun; 24(6):447-8. PubMed ID: 12848906
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk factors for the severity of erosive esophagitis in Helicobacter pylori-negative patients with gastroesophageal reflux disease.
    El-Serag HB; Johanson JF
    Scand J Gastroenterol; 2002 Aug; 37(8):899-904. PubMed ID: 12229963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.